Latest Stock Market News

The Relative Strength Index of the stock stood at 45.78 on Friday.

Eris Lifesciences, incorporated in the year 2007, is a Mid Cap company (having a market cap of Rs 7871.82 Crore) operating in Pharmaceuticals sector.

Volumes have been scaling up, driven by an uptrend in option volumes and recommencement of mini contracts.

The stock rallied from Rs 180 as on 28 February 2023 to Rs 217 recorded on 15 March which translates into an upside of about 21%.The recent momentum helped the stock to hit a fresh 52-week high of Rs 233.50 on 13 March 2023

While exits are possible, it must be pointed out that Krithivasan was a clear frontrunner in case Rajesh ever wished to step down. The question that we have been asked is why appoint Krithivasan when age is not on his side; after all, Krithivasan is 57 years old

“Amidst the intense tug of war, the Nifty50 index concluded the weekly expiry session on a subdued note, with mere gains of 0.08% and settled a tad below the 17000 mark,” Chavan said.

With the cooling off of input prices, correction in logistics cost, higher revenue recognition for its two FGD projects and the international subsidiaries expecting to be profitable within a year, the EBIT margin on an overall level is expected to be between 8-9% in the medium term.

As of 31-Dec-2022, promoters held 0.0 per cent stake in the company, while FIIs held 6.74 per cent and domestic institutional investors had 3.33 per cent.

The stock quoted a 52-week high of Rs 817.95 and a 52-week low of Rs 594.0.

The texture of the chart formation and technical indicators such as RSI is indicating at a likely reversal from the current levels, which could lead to a new leg of the up move from its demand zone.In the near term, 268 would be the immediate support zone for the stock. Above the same, the stock may witness a pullback rally towards 299